Baxter International Inc (BAX) KPIs and segments
Close on Nov 18, 2026Market cap $13.53BP/E –Yield 1.99%
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Baxter International · năm tài chính kết thúc ngày 31 tháng 12
Nhìn nhanh KPI của Baxter International: 49 chỉ số vận hành, trong đó có Organic / Operational Sales Growth, Medical Products & Therapies (MPT) và Healthcare Systems & Technologies (HST), lấy từ 146 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Medical Products & Therapies($M)5 | 2,102 | 2,076 | 1,285 | 1,388 | 1,977 | 1,945 | 1,262 | 1,314 | 1,342 | 1,322 | 1,229 | 1,320 | |
Infusion Therapies & Platforms($M) | 1,760 | 1,745 | 1,671 | 1,649 | |||||||||
International($M) | 1,148 | 1,125 | 594 | 668 | 1,069 | 1,034 | 533 | 596 | 580 | 593 | 556 | 598 | |
Infusion Therapies and Technologies($M) | 981 | 1,060 | 1,023 | 1,024 | 994 | 1,022 | 1,070 | 1,045 | 966 | 1,042 | |||
United States($M) | 954 | 951 | 691 | 134 | 908 | 911 | 729 | 718 | 762 | 729 | 673 | 722 | |
Advanced Surgery($M) | 342 | 331 | 304 | 328 | 306 | 296 | 268 | 292 | 272 | 277 | 263 | 278 | |
Healthcare Systems & Technologies($M)4 | 806 | 801 | 705 | 827 | 773 | 767 | 704 | 784 | 752 | 748 | 667 | 795 | |
United States($M) | 601 | 587 | 513 | 586 | 577 | 562 | 518 | 574 | 557 | 550 | 473 | 561 | |
Care and Connectivity Solutions($M) | 498 | 502 | 435 | 537 | 473 | 474 | 427 | 504 | 456 | 452 | 402 | 493 | |
Front Line Care($M) | 308 | 299 | 270 | 290 | 300 | 293 | 277 | 280 | 296 | 296 | 265 | 302 | |
International($M) | 205 | 214 | 192 | 241 | 196 | 205 | 186 | 210 | 195 | 198 | 194 | 234 | |
Pharmaceuticals($M)4 | 621 | 668 | 632 | 612 | 581 | 643 | 588 | 602 | 578 | 597 | |||
International($M) | 441 | 478 | 455 | 425 | 386 | 429 | 410 | 405 | 387 | 388 | |||
Drug Compounding($M) | 320 | 316 | 299 | 280 | 246 | 260 | 267 | 261 | 250 | 237 | |||
Injectables and Anesthesia($M) | 301 | 352 | 333 | 332 | 335 | 383 | 321 | 341 | 328 | 360 | |||
United States($M) | 180 | 190 | 177 | 187 | 195 | 214 | 178 | 197 | 191 | 209 | |||
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)1 | |||||||||||||
United States($M) | 1,595 | 1,595 | 1,435 | 1,552 | 1,544 | 1,536 | 1,490 | 1,510 | 1,500 | 1,492 | 1,348 | 1,502 | |
International($M) | 1,381 | 1,365 | 1,266 | 1,422 | 1,291 | 1,274 | 1,135 | 1,243 | 1,199 | 1,202 | 1,142 | 1,224 | |
Rest of world($M) | 1,024 | 936 | 930 | 838 | 894 | 852 | 855 | 835 | 866 | ||||
Emerging markets($M) | 398 | 355 | 344 | 297 | 349 | 347 | 347 | 307 | 358 | ||||
Medical Products & Therapies($M) | 439 | 400 | 186 | -288 | 411 | 444 | 244 | 217 | 268 | 238 | 227 | 266 | |
Healthcare Systems & Technologies($M) | 139 | 163 | 66 | 41 | 122 | 156 | 93 | 145 | 136 | 120 | 67 | 156 | |
Pharmaceuticals($M) | 46 | 39 | 56 | 64 | 63 | 102 | 58 | 75 | 78 | 117 | |||
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)2 | |||||||||||||
Medical Products & Therapies($M) | 780 | 745 | 504 | 524 | 751 | 788 | 568 | 583 | 608 | 588 | 561 | ||
Healthcare Systems & Technologies($M) | 361 | 399 | 315 | 367 | 359 | 392 | 348 | 414 | 384 | 368 | 321 | ||
Pharmaceuticals($M) | 163 | 165 | 182 | 184 | 185 | 228 | 180 | 195 | 196 | ||||
Remaining performance obligations (RPO)($M) | 7,580 | 7,910 | 8,870 | 9,890 | 10,080 | 10,190 | 2,750 | 4,160 | 5,780 | ||||
Organic / Operational Sales Growth — Continuing Operations(%)5 | 5.0% | 5.0% | -1.0% | 3.0% | 2.0% | 1.0% | 5.0% | 4.0% | 4.0% | 3.0% | 3.0% | ||
U.S. Organic / Operational Sales Growth(%) | 5.0% | 4.0% | -4.0% | -1.0% | -1.0% | -1.0% | 7.0% | ||||||
International Organic / Operational Sales Growth(%) | 6.0% | 5.0% | 3.0% | 8.0% | 5.0% | 3.0% | 3.0% | ||||||
Reported GAAP Net Sales Growth — Continuing Operations(%) | 5.0% | 5.0% | 3.0% | 8.0% | 5.0% | 4.0% | 5.0% | 4.0% | 3.0% | 2.0% | 4.0% | ||
Foreign Exchange (FX) Impact on Sales Growth(%) | -1.0% | -1.0% | -3.0% | -2.0% | -1.0% | 0.0% | 2.0% | 0.0% | 1.0% | 1.0% | -1.0% | ||
Kidney Care MSA Impact on Reported Sales Growth(%) | 1.0% | 1.0% | -1.0% | -3.0% | -3.0% | -4.0% | -3.0% | ||||||
Medical Products & Therapies (MPT) — Organic / Operational Sales Growth(%)4 | 6.0% | 5.0% | -1.0% | 3.0% | 2.0% | 0.0% | 5.0% | 7.0% | 5.0% | 6.0% | 4.0% | ||
Infusion Therapies & Platforms (ITP) — Organic / Operational Growth(%)2 | 4.0% | 4.0% | -3.0% | 1.0% | 0.0% | -1.0% | 5.0% | ||||||
ITP — Reported Sales Growth(%) | 5.0% | 6.0% | 2.0% | 3.0% | 0.0% | -1.0% | 2.0% | ||||||
ITP — Foreign Exchange (FX) Impact(%) | -1.0% | -2.0% | -5.0% | -2.0% | -1.0% | -1.0% | 2.0% | ||||||
Advanced Surgery — Organic / Operational Sales Growth(%)2 | 12.0% | 12.0% | 10.0% | 11.0% | 11.0% | 5.0% | 4.0% | 7.0% | 4.0% | 8.0% | 6.0% | ||
Advanced Surgery — Reported Sales Growth(%) | 12.0% | 12.0% | 13.0% | 12.0% | 13.0% | 7.0% | 2.0% | 7.0% | 2.0% | 7.0% | 7.0% | ||
Advanced Surgery — Foreign Exchange (FX) Impact(%) | 0.0% | 0.0% | -3.0% | -1.0% | -2.0% | -2.0% | 2.0% | 0.0% | 2.0% | 1.0% | -1.0% | ||
Legacy Infusion Therapies & Technologies — Operational Growth (Through Q1 2026)(%) | -5.0% | 1.0% | -4.0% | -1.0% | 6.0% | 7.0% | 5.0% | 6.0% | 4.0% | ||||
Legacy Pharmaceuticals Segment — Operational Growth (Through Q1 2026)(%)2 | 1.0% | 2.0% | 7.0% | 1.0% | 3.0% | 1.0% | 11.0% | 11.0% | 7.0% | ||||
Healthcare Systems & Technologies (HST) — Organic / Operational Sales Growth(%)2 | 4.0% | 4.0% | -2.0% | 4.0% | 2.0% | 2.0% | 6.0% | 1.0% | 1.0% | -9.0% | 7.0% | ||
Care & Connectivity Solutions (CCS) — Organic / Operational Growth(%)2 | 5.0% | 5.0% | 0.0% | 4.0% | 3.0% | 4.0% | 7.0% | 3.0% | 4.0% | -7.0% | 11.0% | ||
CCS — Reported Sales Growth(%) | 5.0% | 6.0% | 2.0% | 7.0% | 4.0% | 5.0% | 6.0% | 3.0% | 4.0% | -6.0% | 12.0% | ||
CCS — Foreign Exchange (FX) Impact(%) | 0.0% | -1.0% | -2.0% | -3.0% | -1.0% | -1.0% | 1.0% | 0.0% | 0.0% | -1.0% | -1.0% | ||
Front Line Care (FLC) — Organic / Operational Growth(%)2 | 3.0% | 2.0% | -4.0% | 3.0% | 1.0% | -1.0% | 5.0% | -2.0% | -4.0% | -12.0% | 2.0% | ||
FLC — Reported Sales Growth(%) | 3.0% | 2.0% | -3.0% | 4.0% | 1.0% | -1.0% | 5.0% | -2.0% | -4.0% | -12.0% | 3.0% | ||
FLC — Foreign Exchange (FX) Impact(%) | 0.0% | 0.0% | -1.0% | -1.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -1.0% | ||
RPO Expected Revenue Recognition — Next Calendar Year (Year + 1 Share)(%)3 | 25.0% | 25.0% | 20.0% | 25.0% | 20.0% | 20.0% | 20.0% | 25.0% | 25.0% | 50.0% | |||
RPO Expected Recognition — Remainder of Current Year (Q1–Q3 Filings)(%) | 10.0% | 10.0% | 25.0% | 5.0% | 10.0% | 15.0% | 25.0% | ||||||
RPO Expected Recognition — Year + 2 Share(%) | 20.0% | 20.0% | 15.0% | 25.0% | 20.0% | 20.0% | 15.0% | 20.0% | 20.0% | 25.0% | |||
RPO Expected Recognition — Year + 3 Share(%) | 20.0% | 20.0% | 15.0% | 15.0% | 15.0% | 15.0% | 15.0% | 20.0% | 20.0% | 15.0% | |||
Medical Equipment Lease Revenue — Infusion Pumps & Smart Beds($M)4 | 102 | 93 | 100 | 93 | 91 | 95 | 106 | 100 | 115 | 89 | 114 | 102 | |
Operating Lease Revenue($M) | 88 | 85 | 90 | 86 | 86 | 87 | 91 | 92 | 102 | 82 | 104 | 95 | |
Variable Usage-Based Lease Revenue($M) | 7 | 7 | 7 | 7 | 5 | 8 | 7 | 6 | 10 | 4 | 8 | 6 | |
Sales-Type Lease Revenue($M) | 7 | 1 | 3 | 0 | 0 | 0 | 8 | 2 | 3 | 3 | 2 | 1 | |
Net Investment in Sales-Type Equipment Leases($M) | 29 | 24 | 30 | 30 | 33 | 38 | 47 | 37 | 36 | 70 | 69 | 50 | |
Customer Contract Assets — Placed Equipment & Software($M)5 | 111 | 122 | 136 | 147 | 138 | 129 | 132 | 133 | 145 | 153 | 156 | 165 | |
Bundled Equipment & Consumable Medical Products Contract Assets($M) | 88 | 92 | 100 | 110 | 99 | 87 | 89 | 87 | 95 | 102 | 108 | 116 | |
Medical Device Software Arrangements Contract Assets($M) | 23 | 27 | 31 | 34 | 34 | 36 | 39 | 44 | 46 | 45 | 41 | 45 | |
Contract Manufacturing Services Contract Assets($M) | 0 | 3 | 5 | 3 | 5 | 6 | 4 | 2 | 4 | 6 | 7 | 4 | |
Current Contract Assets($M) | 62 | 64 | 70 | 71 | 65 | 55 | 54 | 51 | 54 | 53 | 53 | 53 | |
Non-Current Contract Assets($M) | 49 | 58 | 66 | 76 | 73 | 74 | 78 | 82 | 91 | 100 | 103 | 112 | |
Installation & Service Contract Liabilities (Deferred Service Backlog)($M)3 | 161 | 166 | 182 | 177 | 159 | 178 | 175 | 171 | 160 | 156 | 169 | 169 | |
New Installation & Service Revenue Deferrals (Bookings)($M) | 146 | 119 | 187 | 217 | 130 | 130 | 128 | 171 | 183 | 107 | 93 | 77 | |
Installation & Service Contract Revenue Recognized($M) | 152 | 135 | 182 | 207 | 144 | 126 | 124 | 166 | 176 | 122 | 91 | 77 | |
Revenue Recognized from Opening Contract Liability Balance($M) | 35 | 44 | 46 | 26 | 32 | 23 | 34 | 9 | 21 | 30 | 43 | 6 | |
FDA 510(k) Premarket Device Clearances1 | 1 | 1 | 1 | 1 | 3 | 0 | 3 | 1 | 2 | 0 | 5 | 0 | |
FDA Premarket Approvals (PMA & Supplements) | 2 | 1 | 0 | 2 | 2 | 4 | 1 | 2 | 4 | 2 | 2 | 3 | |
FDA Medical Device Recall Events (openFDA)1 | 12 | 2 | 3 | 18 | 10 | 16 | 25 | 42 | 15 | 11 | 27 | 3 | |
FDA Device Enforcement Reports | 12 | 2 | 3 | 19 | 9 | 32 | 11 | 40 | 16 | 15 | 22 | 4 | |
FDA MAUDE Medical Device Adverse Event Reports — Total3 | 2,734 | 2,943 | 2,889 | 3,373 | 3,047 | 3,553 | 4,282 | 4,767 | 4,171 | 3,988 | 3,659 | 4,037 | |
Infusion Therapies & Platforms (ITP) — U.S. Net Sales($M)1 | 768 | 769 | 711 | 728 | 740 | 753 | 786 | 779 | 794 | 792 | 728 | ||
ITP — U.S. Reported Sales Growth(%) | 4.0% | 2.0% | -10.0% | -7.0% | -7.0% | -5.0% | 8.0% | ||||||
Infusion Therapies & Platforms (ITP) — International Net Sales($M)1 | 992 | 976 | 905 | 1,007 | 931 | 896 | 804 | 898 | 881 | 877 | 832 | ||
ITP — International Reported Sales Growth(%) | 7.0% | 9.0% | 13.0% | 12.0% | 6.0% | 2.0% | -3.0% | ||||||
Advanced Surgery — U.S. Net Sales($M)1 | 186 | 182 | 165 | 177 | 168 | 158 | 145 | 157 | 149 | 150 | 147 | 149 | |
Advanced Surgery — U.S. Reported Sales Growth(%) | 11.0% | 15.0% | 14.0% | 13.0% | 13.0% | 5.0% | -1.0% | 7.0% | 0.0% | 2.0% | 2.0% | ||
Advanced Surgery — International Net Sales($M)1 | 156 | 149 | 139 | 151 | 138 | 138 | 123 | 135 | 123 | 127 | 116 | 129 | |
Advanced Surgery — International Reported Sales Growth(%) | 13.0% | 8.0% | 13.0% | 12.0% | 12.0% | 9.0% | 6.0% | 6.0% | 4.0% | 14.0% | 13.0% | ||
Care & Connectivity Solutions (CCS) — U.S. Net Sales($M)1 | 362 | 361 | 315 | 367 | 348 | 341 | 316 | 366 | 335 | 332 | 278 | 337 | |
CCS — U.S. Reported Sales Growth(%) | 4.0% | 6.0% | 0.0% | 0.0% | 4.0% | 3.0% | 14.0% | 6.0% | 7.0% | -7.0% | 11.0% | ||
Care & Connectivity Solutions (CCS) — International Net Sales($M)1 | 136 | 141 | 120 | 170 | 125 | 133 | 111 | 138 | 121 | 120 | 124 | 156 | |
CCS — International Reported Sales Growth(%) | 9.0% | 6.0% | 8.0% | 23.0% | 3.0% | 11.0% | -10.0% | -4.0% | -4.0% | -5.0% | 13.0% | ||
Front Line Care (FLC) — U.S. Net Sales($M)1 | 239 | 226 | 198 | 219 | 229 | 221 | 202 | 208 | 222 | 218 | 195 | 224 | |
FLC — U.S. Reported Sales Growth(%) | 4.0% | 2.0% | -2.0% | 5.0% | 3.0% | 1.0% | 4.0% | -5.0% | -4.0% | -12.0% | 0.0% | ||
Front Line Care (FLC) — International Net Sales($M)1 | 69 | 73 | 72 | 71 | 71 | 72 | 75 | 72 | 74 | 78 | 70 | 78 | |
FLC — International Reported Sales Growth(%) | -3.0% | 1.0% | -4.0% | -1.0% | -4.0% | -8.0% | 7.0% | 10.0% | -3.0% | -14.0% | 13.0% | ||
Kidney Care MSA & Other Unallocated Revenue($M)3 | 68 | 83 | 76 | 84 | 85 | 98 | 63 | 0 | 0 | 0 | 0 | 18 | |
Kidney Care MSA & Other — U.S. Net Sales($M) | 40 | 57 | 46 | 61 | 59 | 63 | 41 | 0 | 0 | 0 | 0 | 14 | |
Kidney Care MSA & Other — International Net Sales($M) | 28 | 26 | 30 | 23 | 26 | 35 | 22 | 0 | 0 | 0 | 0 | 4 | |
Other / Kidney Care MSA Operating Income (Loss)($M) | 10 | 6 | 7 | 5 | 5 | 6 | 6 | -12 | -1 | 5 | -4 | -1 | |
Legacy Infusion Therapies & Technologies — U.S. Net Sales (Through Q1 2026)($M)3 | 526 | 543 | 555 | 554 | 584 | 561 | 613 | 579 | 526 | 573 | |||
Medical Products & Therapies (MPT) — Segment Operating Margin(%)2 | 20.9% | 19.3% | 14.5% | 15.4% | 20.5% | 18.1% | 19.3% | ||||||
Healthcare Systems & Technologies (HST) — Segment Operating Margin(%) | 17.2% | 20.3% | 9.4% | 15.2% | 13.5% | 15.4% | 13.2% | ||||||
Legacy Pharmaceuticals Segment — Operating Margin (Through Q1 2026)(%) | 7.4% | 5.8% | 8.9% | 10.5% | 10.8% | 9.9% | 7.4% | 14.4% | 8.0% | ||||
Adjusted Operating Income — Continuing Operations (Non-GAAP)($M)5 | 432 | 421 | 297 | 352 | 423 | 423 | 392 | 391 | 522 | 515 | 630 | ||
Adjusted Diluted EPS — Continuing Operations (Non-GAAP)($) | 0.58 | 0.56 | 0.36 | 0.44 | 0.69 | 0.59 | 0.55 | 0.49 | 0.68 | 0.65 | 0.88 | ||
Full-Year Adjusted Diluted EPS Guidance — Low($) | 2.05 | 1.95 | 1.85 | 1.85 | |||||||||
Full-Year Adjusted Diluted EPS Guidance — High($) | 2.15 | 2.15 | 2.05 | 2.05 | |||||||||
Free Cash Flow — Continuing Operations (Non-GAAP)($M) | 448 | 181 | 76 | -221 | 0 | ||||||||
Unallocated Corporate Costs($M) | 156 | 148 | 159 | 241 | 115 | 183 | 139 | 161 | 182 | 170 | 210 | 0 | |
Hurricane Helene North Cove Plant Remediation & Recovery Costs($M)4 | 3 | 3 | 3 | 10 | 8 | 17 | 98 | 85 | 25 | 0 | 0 | ||
Product-Related & Infusion Pump Field Corrective Action Charges (Net)($M) | 0 | 0 | -12 | 52 | 32 | 23 | 6 | 12 | 3 | 0 | 0 | 0 | |
European Medical Devices Regulation (EU MDR) Compliance Costs($M) | 3 | 4 | 4 | 6 | 5 | 5 | 5 | 8 | 9 | 9 | 7 | 10 | |
Kidney Care (Vantive) & Spin-Off Separation Costs($M) | 2 | 22 | 11 | 18 | 13 | 14 | 13 | 0 | 0 | 0 | 0 | 102 | |
Business Transformation Program Costs($M) | 20 | 23 | 11 | 0 | 0 | ||||||||
Business Optimization & Restructuring Special Charges($M)3 | 61 | 7 | 68 | 78 | 38 | 17 | 45 | 113 | 18 | 9 | 22 | 26 | |
Restructuring — Employee Severance & Termination Costs($M) | 21 | 0 | 58 | 60 | 18 | 5 | 26 | 69 | 12 | 3 | 14 | -3 | |
Restructuring — Asset Impairments & Write-Offs($M) | 33 | 0 | 1 | 6 | 9 | 5 | 18 | 8 | 5 | 7 | |||
Restructuring — Contract Termination & Exit Costs($M) | 8 | 2 | 2 | 1 | 10 | 4 | 2 | 3 | 1 | 3 | -3 | ||
Inventories — Finished Goods($M)3 | 1,311 | 1,278 | 1,359 | 1,327 | 1,576 | 1,494 | 1,310 | 1,270 | 1,315 | 1,927 | 1,922 | 1,154 | |
Inventories — Raw Materials($M) | 560 | 555 | 567 | 536 | 573 | 587 | 550 | 510 | 532 | 750 | 750 | 530 | |
Inventories — Work in Process($M) | 429 | 426 | 390 | 369 | 311 | 303 | 310 | 266 | 256 | 308 | 316 | 234 | |
Allowance for Credit Losses on Accounts Receivable($M) | 55 | 56 | 67 | 63 | 69 | 71 | 66 | 71 | 65 | 123 | 121 | 62 | |
Property, Plant & Equipment — Gross Carrying Value($M)3 | 8,204 | 8,177 | 8,099 | 8,054 | 7,750 | 7,688 | 7,431 | 7,648 | 7,605 | 10,774 | 11,197 | 7,650 | |
Accumulated Depreciation & Amortization on PP&E($M) | 5,331 | 5,264 | 5,186 | 5,144 | 4,938 | 4,886 | 4,714 | 4,778 | 4,772 | 6,460 | 6,827 | 4,779 | |
Intangible Asset Amortization Expense($M) | 145 | 145 | 146 | 145 | 147 | 151 | 155 | 154 | 159 | 154 | 158 | 156 | |
Operating Lease Right-of-Use Assets Obtained($M) | 12 | 3 | 20 | 22 | 2 | 7 | 5 | 10 | 23 | 15 | 16 | 11 | |
Discontinued Operations (Kidney Care / Vantive & BioPharma Solutions) — Operating Cash Flow($M) | 0 | -12 | 0 | -12 | 0 | 0 | -94 | 45 | -93 | 152 | 96 | 116 | |
U.S. Federal Contract Action Obligations — Baxter Healthcare (VA, DoD & HHS)($M) | 14.5 | 0.56 | 0.23 | 0.62 | 5.54 | -0.01 | 0.22 | 1.80 | 0.58 | 10.3 | 0.36 | 1.50 | |
U.S. General Medical & Surgical Hospitals Revenue (Census QSS)($M) | 47,896 | 46,674 | 46,834 | 46,295 | 45,370 | 45,358 | 45,284 | 43,778 | 43,505 | 43,709 | 43,264 | ||
Total U.S. MedTech Industry — FDA 510(k) Clearances1 | 856 | 923 | 756 | 806 | 797 | 886 | 736 | 856 | 767 | 793 | 713 | 877 | |
Total U.S. MedTech Industry — FDA PMA Approvals | 565 | 608 | 567 | 525 | 585 | 588 | 524 | 683 | 538 | 550 | 459 | 656 | |
Consolidated Net Sales (Continuing Operations)($M)6 | 2,976 | 2,960 | 2,701 | 2,974 | 2,835 | 2,810 | 2,625 | 2,753 | 2,699 | 2,694 | 2,490 | 2,729 | |
Gross Profit($M) | 994 | 1,032 | 891 | 577 | 950 | 991 | 861 | 959 | 1,033 | 1,031 | 961 | 1,100 | |
Selling, General & Administrative Expenses($M) | 730 | 735 | 728 | 761 | 708 | 718 | 703 | 761 | 754 | 723 | 729 | 683 | |
Research & Development Expenses($M) | 125 | 129 | 139 | 126 | 118 | 134 | 140 | 211 | 129 | 130 | 120 | 127 | |
Operating Income (Loss)($M) | 225 | 217 | 66 | -729 | 172 | 191 | 58 | -435 | 155 | 179 | 115 | 304 | |
Income (Loss) from Continuing Operations($M) | 298 | 135 | -17 | -1,035 | -51 | 122 | 64 | -488 | 61 | 95 | 6 | 219 | |
Net Income (Loss) Attributable to Baxter Stockholders($M) | 294 | 126 | -15 | -1,128 | -46 | 91 | 126 | -512 | 140 | -314 | 37 | 245 | |
Operating Cash Flow($M)2 | 558 | 285 | 213 | 584 | 237 | 217 | -193 | 488 | 253 | 115 | 163 | 531 | |
Depreciation & Amortization($M) | 239 | 239 | 237 | 240 | 237 | 257 | 247 | 245 | 254 | 227 | 271 | 264 | |
Stock-Based Compensation($M) | 30 | 33 | 10 | 37 | 35 | 35 | 10 | 39 | 38 | 20 | 17 | 25 | |
Total Assets($M)6 | 19,414 | 19,791 | 19,846 | 20,055 | 21,067 | 21,046 | 21,304 | 25,782 | 26,676 | 26,312 | 27,788 | 28,276 | |
Cash & Cash Equivalents($M) | 1,975 | 2,150 | 2,017 | 1,966 | 1,726 | 1,686 | 2,294 | 1,764 | 1,420 | 1,574 | 2,826 | 3,078 | |
Accounts Receivable, Net($M) | 1,783 | 1,856 | 1,698 | 1,861 | 1,777 | 1,773 | 1,646 | 1,679 | 1,729 | 2,639 | 2,521 | 1,719 | |
Total Inventories, Net($M) | 2,300 | 2,259 | 2,316 | 2,232 | 2,460 | 2,384 | 2,170 | 2,046 | 2,103 | 2,985 | 2,988 | 1,918 | |
Goodwill($M) | 4,871 | 4,886 | 4,899 | 4,929 | 5,400 | 5,395 | 5,338 | 5,275 | 5,783 | 6,001 | 6,430 | 5,793 | |
Other Intangible Assets, Net($M) | 3,927 | 4,073 | 4,218 | 4,369 | 4,805 | 4,950 | 5,081 | 5,223 | 5,449 | 5,741 | 5,905 | 5,918 | |
Total Liabilities($M) | 12,939 | 13,612 | 13,830 | 13,953 | 13,853 | 13,753 | 14,250 | 18,758 | 18,734 | 18,604 | 19,553 | 19,808 | |
62 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Baxter International Inc.'s latest reported fiscal period is Q3 2026 (ended September 30, 2026; Form 8-K Earnings Release & Form 10-Q filed October 29, 2026; FY2025 Form 10-K filed February 12, 2026).
- Q2 2026 Segment Realignment & Kidney Care Divestiture: Beginning in Q2 2026 (recast via Form 8-K filed July 14, 2026), Baxter folded its former Pharmaceuticals segment (Injectables & Anesthesia and Drug Compounding) into the Infusion Therapies & Platforms (ITP) division of Medical Products & Therapies alongside Advanced Surgery, while Healthcare Systems & Technologies comprises Care & Connectivity Solutions and Front Line Care. All continuing operations exclude the former Kidney Care segment (Vantive), divested to Carlyle on January 31, 2025 (~$3.8B purchase price); ongoing Manufacturing and Supply Agreement (MSA) revenues to Vantive are reported in Other.
- Commercial Equipment Placement & Leasing Model: Baxter places infusion systems (Spectrum IQ, Novum IQ) and hospital smart beds (Progressa+, Centrella) under ASC 842 operating, variable usage-based, and sales-type leases ($385M lease revenue and $375M gross customer-leased equipment fleet in FY2025) as well as bundled upfront equipment-and-consumable contracts ($110M contract asset at FY2025, collected over 1–7 years) and installation/maintenance service deferrals ($605M new deferrals in FY2025).
- Subsidiary & Standalone Scope: Baxter files consolidated U.S. GAAP financial statements without standalone parent-only financial statements; all principal operating subsidiaries (including Hill-Rom Services, Inc., Welch Allyn Inc., and Baxter Healthcare Limited in the UK) are 100% wholly owned. Statutory annual workforce pay disclosures of UK operating subsidiary Baxter Healthcare Limited (Co. No. 00461365) are included.
- Methodology: Every value is directly as published in SEC filings, Baxter Corporate Responsibility Reports, U.S. FDA openFDA, ClinicalTrials.gov, USAspending.gov, UK Government statutory filings, or BLS/Census FRED series. The only derived cells are discrete quarterly splits from cumulative year-to-date disclosures (quarter = YTD minus prior YTD; Q4 = full year minus nine months), displayed in italics with their exact formula.
Không hiện vì thiếu các kỳ gần đây (8)
- Remaining Performance Obligations Total Dollar Balance ($7.58B at Q3 2026) — Already displayed automatically in the Core XBRL KPI section via us-gaap:RevenueRemainingPerformanceObligation; maturity recognition percentages (Remainder of Year, Year+1, Year+2, Year+3) are tracked in Group 2.
- Top-Level GAAP Segment Net Sales & Operating Income (Medical Products & Therapies, Healthcare Systems & Technologies, legacy Pharmaceuticals, and consolidated U.S. / International totals) — Already displayed automatically by the Segment XBRL view; granular U.S. vs. International division net sales, Kidney Care MSA revenues, and organic constant-currency growth bridges are tracked in Groups 1 and 4.
- Global Commercial Reach ('sold in over 100 countries' and 'manufactured in more than 20 countries' in Form 10-K Item 1) — Disclosed only as lower bounds ('over 100', 'more than 20') rather than exact point counts.
- Patients Supported Worldwide ('approximately 350 million patients annually' / 'more than 350 million patients' in Proxy Statement) — Disclosed only in promotional narrative with bound qualifiers across fewer than two consecutive comparable periods.
- Full-Year 2026 Organic Sales Growth Guidance in Q4 2025 & Q1 2026 ('approximately flat') — Stated qualitatively without numerical range bounds in Q4 2025 and Q1 2026 prior to numerical range resumption ('2% to 3%' in Q2 2026 and '3% to 4%' in Q3 2026).
- Care & Connectivity Solutions U.S. Capital Orders Growth (+9% in Q4 2024, 'over 30%' in Q4 2025) — Disclosed intermittently on fourth-quarter earnings calls and as a lower bound ('over 30%') in Q4 2025.
- North Cove Facility Manufacturing Lines Restarted Post-Hurricane Helene (8 of 10 lines in Q4 2024; final 2 lines in January 2025) — One-time post-hurricane recovery milestone disclosed in Q4 2024 commentary rather than a recurring quarterly series.
- 2025 Sustainability Report Annual Environmental & Safety Metrics (FY2025) — Hosted on investor.baxter.com behind a Cloudflare Turnstile challenge gate; historical multi-year assured data through FY2024 is presented from open public Corporate Responsibility Reports.
Dữ liệu cập nhật 2026-11-18.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Organic & Constant-Currency Sales Growth Bridge (Key #1)
Equipment Leasing, Bundled Contracts & RPO Schedule (Key #2)
FDA Clearances, Quality Surveillance & Clinical Pipeline (Key #3)
Division × Geography Net Sales & Kidney Care MSA (Key #4)
- Infusion Therapies & Platforms (ITP) — U.S. Net Sales ($M)11 kỳ
- Infusion Therapies & Platforms (ITP) — International Net Sales ($M)11 kỳ
- Advanced Surgery — U.S. Net Sales ($M)17 kỳ
- Advanced Surgery — International Net Sales ($M)17 kỳ
- Care & Connectivity Solutions (CCS) — U.S. Net Sales ($M)17 kỳ
- Care & Connectivity Solutions (CCS) — International Net Sales ($M)17 kỳ
- Front Line Care (FLC) — U.S. Net Sales ($M)17 kỳ
- Front Line Care (FLC) — International Net Sales ($M)17 kỳ
- Kidney Care MSA & Other Unallocated Revenue ($M)17 kỳ
- Legacy Infusion Therapies & Technologies — U.S. Net Sales (Through Q1 2026) ($M)15 kỳ
Segment Operating Margin, Hurricane Helene & Remediation Items
Manufacturing Inventory Stages, Plant Footprint & Capital Assets
U.S. Federal Hospital Supply Contracts (USAspending.gov)
Workforce, 3TG Supply Chain, CEO Pay & UK Subsidiary (Baxter Healthcare Ltd)
Environmental Sustainability & Plant Safety (Water, Energy, GHG & TRIR)
- Operational Water Withdrawal — Total (Thousand Cubic Meters)8 kỳ
- Operational Energy Usage — Total (Thousand MWh)8 kỳ
- Operational GHG Emissions — Scope 1 & 2 (Metric Tons CO2e)8 kỳ
- Total Manufacturing & Operational Waste (Metric Tons)8 kỳ
- Employee Total Recordable Incident Rate (TRIR per 200,000 Hours) (×)8 kỳ
Industry & Macro MedTech Benchmarks (BLS, Census & U.S. FDA)
- U.S. Producer Price Index (PPI): Surgical & Medical Instruments (NAICS 339112) (×)130 kỳ
- U.S. Producer Price Index (PPI): Surgical Appliances & Supplies (NAICS 339113) (×)130 kỳ
- U.S. Producer Price Index (PPI): Electromedical Apparatus (NAICS 334510) (×)130 kỳ
- U.S. Consumer Price Index (CPI-U): Medical Care Commodities (×)129 kỳ
- U.S. Consumer Price Index (CPI-U): Medical Care Services (×)129 kỳ
- U.S. General Medical & Surgical Hospitals Revenue (Census QSS) ($M)42 kỳ
- Total U.S. MedTech Industry — FDA 510(k) Clearances130 kỳ
Consolidated Financial Context (US GAAP)
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Baxter International
- Baxter Form 10-Q (FY2026Q3, filed 2026-10-29) ↗
- Baxter Form 10-K (FY2025, filed 2026-02-12) ↗
- Baxter Form 8-K Earnings Release (FY2026Q3, filed 2026-10-29) ↗
- Baxter Form 8-K Exhibit 99.1 — Revised Segment Net Sales & Operating Income (2026-07-14) ↗
- U.S. FDA openFDA Premarket Notification 510(k) Database (Baxter, Hill-Rom, Welch Allyn & Synovis) ↗
- Baxter 2024 Corporate Responsibility Report ↗
- U.S. FDA openFDA Medical Device Recalls & Enforcement Database ↗
- U.S. FDA MAUDE Adverse Event Reporting Database (MDRs) ↗
- Baxter SEC Form 10-Q (filed 2026-10-29) ↗
- Baxter SEC Form 10-K (filed 2026-02-12) ↗
- Baxter Form 8-K Earnings Release (FY2025Q4, filed 2026-02-12) ↗
- USAspending.gov Federal Award Data (Recipient: Baxter Healthcare) ↗
See a number that looks wrong?